SAROJA PHARMA INDUS IND L Fair Value
SAROJA · Chemicals · Current price ₹40.95
| Method | Fair value | Status |
|---|---|---|
| Residual income | ₹39 | 7% ROE fading to 14% over ~3 yrs, on ₹43 book |
| Relative P/E | ₹182 | EPS × 45.2 peer-median P/E |
| Graham floor | ₹62 | Conservative floor: √(22.5 × EPS × book value/share) |
| Analyst target | — | No analyst coverage |
Is SAROJA PHARMA INDUS IND L undervalued?
DocStoX estimates the fair value of SAROJA PHARMA INDUS IND L at ₹81 per share, versus the current market price of ₹41. That puts the stock about +97.9% below our fair-value estimate, which we read as "Buy". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 3 independent methods: Residual income (₹39), Relative P/E (₹182), Graham floor (₹62). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹39 (bear) to ₹81 (base) to ₹182 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
More on SAROJA PHARMA INDUS IND L
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.